Candesartan Cilexetil-d11

Candesartan Cilexetil-d11 (TCV-116-d11) is deuterium labeled Candesartan Cilexetil. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure[1][2][3][4][5][6].

Product Specifications

CAS Number

[1261393-19-4]

Product Name Alternative

TCV-116-d11

UNSPSC

12352005

Target

Angiotensin Receptor; Apoptosis; Isotope-Labeled Compounds

Related Pathways

Apoptosis; GPCR/G Protein; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cardiovascular Disease; Endocrinology

Smiles

O=C(C1=CC=CC2=C1N(C(OCC)=N2)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5)OC(OC(OC6(C([2H])(C([2H])(C([2H])(C([2H])(C6([2H])[2H])[2H])[2H])[2H])[2H])[2H])=O)C

Molecular Formula

C33H23D11N6O6

Molecular Weight

621.73

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Loe M W C, et al. Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection [J]. Antiviral Research, 2019, 172: 104637.|[3]Kobayashi N, et al. Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats [J]. Atherosclerosis, 2001, 156 (2) : 255-265.|[4]Takeda H, et al. Effects of angiotensin II receptor signaling during skin wound healing [J]. The American journal of pathology, 2004, 165 (5) : 1653-1662.|[5]McClellan K J, et al. Candesartan cilexetil: a review of its use in essential hypertension [J]. Drugs, 1998, 56: 847-869.|[6]Kojima M, et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro [J]. Circulation, 1994, 89 (5) : 2204-2211.|[7]Otsuka M, et al. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist [J]. Thorax, 2004, 59 (1) : 31-38.